UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed solid tumor that is metastatic or unresectable and for which no standard curative or palliative measures exist or are effective
• No brain metastases or primary CNS malignancy
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm3
• Platelet count at least 100,000/mm3
• Hepatic
• Bilirubin no greater than 1.5 mg/dL
• AST and ALT no greater than 3 times upper limit of normal
• Renal
• Creatinine no greater than 1.5 mg/dL OR
• Creatinine clearance at least 60 mL/min
• Cardiovascular
• No known active coronary artery disease
• Pulmonary
• No pulmonary dysfunction
• Other
• HIV negative
• No history of unusually severe and/or prolonged toxicity during prior therapy with fluorouracil (5-FU) or 5-FU prodrugs
• No diabetes mellitus requiring insulin or oral hypoglycemic therapy
• No ongoing or active infection requiring IV antibiotics
• No other serious concurrent medical illness that would preclude study
• No psychiatric illness or social situations that would preclude study
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• At least 4 weeks since prior immunotherapy and recovered
• No concurrent cytokines during the first course of therapy
• Chemotherapy
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Endocrine therapy
• No concurrent systemic corticosteroids
• Radiotherapy
• At least 2 weeks since prior radiotherapy and recovered
• No prior pulmonary or mediastinal radiation exceeding 40 Gy
• Surgery
• Recovered from prior surgery
• Other
• No other concurrent investigational agents
• No concurrent cimetidine
• No concurrent sorivudine or brivudine